Last reviewed · How we verify

NCT03593148: LIFETIME

The Effect of Lifestyle Treatment in Patients With Morbid Obesity

Status unknown NA Last updated 1 September 2021
What this trial tests

NA trial testing Lifestyle in Physical Capacity in 600 participants. Status unknown.

Timeline
1 April 2017
Primary endpoint
23 December 2025
23 December 2025

Quick facts

Lead sponsorSykehuset i Vestfold HF
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment600
Start date1 April 2017
Primary completion23 December 2025
Estimated completion23 December 2025
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Sykehuset i Vestfold HF — full company profile →

Who can join

Adults 18 to 99, any sex, with Physical Capacity or Leg Strength. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effect of lifestyle treatment on physical capacity, maximal strength, eating behavior and quality of life in patients with morbid obesity (LIFETIME)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Machine Learning for Estimating Cardiorespiratory Fitness in Patients With Obesity: Protocol for a Retrospective and Prospective Multicenter Cohort Study.
    Berge J, Nunavath V, Asbjørnsen RA, Borgeraas H, et al · · 2026 · PMID 41773679 · DOI 10.2196/85069

Verify or expand the search:

Other trials of Lifestyle

Trials testing the same drug.

Other Sykehuset i Vestfold HF trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03593148.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing